Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9.
Björntorp P. Abdominal obesity and the metabolic syndrome. Ann Med 1992; 24: 465-8.
Mykkänen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 1998; 47:793-800.
DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-94.
Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149: 151420.
Liese AD, Mayer-Davis EJ, Tyroler HA, Davis CE, Keil U, Duncan BB, et al. Development of the multiple metabolic syndrome in the ARIC cohort: joint contribution of insulin, BMI, and WHR. Atherosclerosis risk in communities. Ann Epidemiol 1997; 7: 407-16.
Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486-97.
Grundy SM. Cholesterol-lowering clinical trials: a historical perspective. In:Grundy SM, editor. Cholesterol-lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker; 2000. p. 1-44.
Gadi R, Samaha FF. Dyslipidemia in type 2 diabetes mellitus. Curr Diab Rep 2007; 7: 228-34.
Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence. J Intern Med 2006; 259: 493-519.
Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003; 361: 777-80.
Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-33.
Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
Wägner AM, Pérez A, Zapico E, Ordóñez-Llanos J. Non-HDL cholesterol and apolipoprotein B in the dyslipidemic classification of type 2 diabetic patients. Diabetes Care 2003; 26: 2048-51.
Kim H, Yi S, Son EI, Kim J. Differential effects of left versus right mesial temporal lobe epilepsy on Wechsler intelligence factors. Neuropsychology 2003;17: 556-65.
Bae Y, Rhew JY, Cho IJ, Ryu MH, Seo JP, Gill GC, et al. A study of plasma apolipoprotein A-1 and apolipoprotein B levels in patients with coronary artery disease. Korean Circ J 1995; 25: 967-74.
Park HS, Kim YS, Min WK, Lee CW, Park SW, Park SJ. A case-control study on the risk factors for coronary artery disease among Korean. Korean Circ J 1998; 28: 849-62.
Hwang ST, Kim BJ, Kim ER, Shin HS, Sung KC, Kim BS, et al. Concordance/discordance between apolipoprotein B levels and the cholesterol indexes. Korean Circ J 2005; 35: 436-42.
Sierra-Johnson J, Somers VK, Kuniyoshi FH, Garza CA, Isley WL, Gami AS, et al. Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. Am J Cardiol 2006; 98: 1369-73.
Alfadda AA, Al-Daghri NM, Malabu UH. Apolipoprotein B/apolipoprotein A-I ratio in relation to various definitions of metabolic syndrome among Saudi patients with type 2 diabetes mellitus. Saudi Med J 2008; 29: 821-5.
Hwang ST, Sung KC, Kim BJ, Kim BS, Kang JH, Lee MH, et al. Insulin resistance and apolipoprotein B as a metabolic syndrome risk factor in normal glucose tolerance. Korean J Med 2004; 66: 156-66.
Grundy SM. Approach to lipoprotein management in 2001 National Cholesterol Guidelines. Am J Cardiol 2002; 90: 11i-21i.
Jiang R, Schulze MB, Li T, Rifai N, Stampfer MJ, Rimm EB, et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 2004; 27: 1991-7.
Taghibiglou C, Rashid-Kolvear F, Van Iderstine SC, Le-Tien H, Fantus IG, Lewis GF, et al. Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance. J Biol Chem 2002; 277: 793-803.
Relimpio F, Losada F, Pumar A, Mangas MA, Morales F, Astorga R. Relationships of apolipoprotein B(100) with the metabolic syndrome in Type 2 diabetes mellitus. Diabetes Res Clin Pract 2002; 57: 199-207.
Kang YH, Yi DW. Significance of ApoB and ApoB/A-I as a marker of metabolic syndrome in type 2 diabetes. Journal of Pusan National University Hospital 2011; 29: 24-35.
Watts GF, Chan DC, Ooi EM, Nestel PJ, Beilin LJ, Barrett PH. Fish oils, phytosterols and weight loss in the regulation of lipoprotein transport in the metabolic syndrome: lessons from stable isotope tracer studies. Clin Exp Pharmacol Physiol 2006; 33: 877-82.
Matthan NR, Welty FK, Barrett PH, Harausz C, Dolnikowski GG, Parks JS, et al. Dietary hydrogenated fat increases high-density lipoprotein apoA-I catabolism and decreases low-density lipoprotein apoB-100 catabolism in hypercholesterolemic women. Arterioscler Thromb Vasc Biol 2004; 24:1092-7.
Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. BMJ 1989;298: 784-8.
Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994; 106: 241-53.